Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 04:36:18 2025-01-21 am EST			5-day change	1st Jan Change
565.35 ^DKK	+2.55%		-5.34%	-10.17%

Jan. 03	New Year, Soft Start
Jan. 03	BNP Paribas Exane Cuts Novo Nordisk PT, Maintains at Outperform	MT

Ozempic, Wegovy and other new drugs are selected for Medicare's price negotiations

January 17, 2025 at 09:12 am EST

WASHINGTON (AP) — Popular weight loss drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers, the Biden administration said Friday.

The price negotiations for the additional 15 drugs selected will be handled by the incoming Trump administration and almost assures billions of dollars in savings for taxpayers.

Ozempic and Wegovy are made by Novo Nordisk, which is based in Denmark and has U.S. headquarters Plainsboro, New Jersey.

Latest news about Novo Nordisk A/S

New Year, Soft Start	Jan. 03
BNP Paribas Exane Cuts Novo Nordisk PT, Maintains at Outperform	Jan. 03	MT
Jyske Bank Cuts Novo Nordisk PT, Retains Buy Rating	Jan. 03	MT
BNP Paribas Exane lowers target price for Novo Nordisk to DKK 745 (930), reiterates outperform - BN	Jan. 03	FW
Jyske Bank cuts target price for Novo Nordisk to DKK 850 (1,000), reiterates Buy - BN	Jan. 03	FW
A poor 2024 increases the odds of a brighter 2025	Jan. 02
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	Dec. 31	MT
Nordnet savers bottom-fished in December, sold off Tesla	Dec. 30	FW
Avanza savers bought Evolution, Novo Nordisk and Apotea in December, sold US	Dec. 30	FW
Retail investors buy Novo dip after disappointing weight-loss drug data	Dec. 24	RE
UK's Hikma Cleared to Launch Generic Form of Novo Nordisk's Diabetes Injection in US	Dec. 24	MT
Hikma Pharmaceuticals Wins US FDA Nod for Generic Version of Novo Nordisk's Diabetes Drug	Dec. 23	MT
Health Care Up on Defensive Bias -- Health Care Roundup	Dec. 23	DJ
NOVO NORDISK : Buy rating from Barclays	Dec. 23	ZD
DAX Index Falls as German Import Prices Rise	Dec. 23	MT
European Equities Traded in the US as American Depositary Receipts Start Week Down Slightly in Monday Trading	Dec. 23	MT
Stifel lowers target price for Novo Nordisk to DKK 780 (955), reiterates Buy - BN	Dec. 23	FW
Novo Nordisk and Gerresheimer recover after 'overreaction'	Dec. 23	DP
Svenska Handelsbanken Upgrades Novo Nordisk to Outperform	Dec. 23	MT
Oddo BHF Keeps Novo Nordisk at Neutral, Cuts PT	Dec. 23	MT
Stocks Mostly Down Pre-Bell Ahead of Holiday-Shortened Trading Week; Asia, Europe Up	Dec. 23	MT
AlphaValue/Baader Europe: Novo Nordisk's New Obesity Drug Holds Promise Despite Disappointing Late-Stage Data	Dec. 23	MT
European Midday Briefing : Stocks Lack Momentum to Start Shortened Week	Dec. 23	DJ
NOVO NORDISK : DZ Bank is Neutral	Dec. 23	ZD
STOXX 600 inches lower at start of Christmas week; Novo Nordisk surges	Dec. 23	RE

Chart Novo Nordisk A/S

Duration

Period

NOVO B: Dynamic Chart

Company Profile

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).

Employees

71,880

Sector

Pharmaceuticals

Calendar

2025-02-05 - Q4 2024 Earnings Release

More about the company